← Back to Analyst Consensus 
ATOS Buy
ATOSSA THERAPEUTICS, INC.
Current Price —
Implied Upside —
Analysts 8
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 1 reiterations from 1 firms
Next Earnings
Nov 10, 2026 (15 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 1, 2026 | Ascendiant Capital | maintain | Buy → Buy | — | 38% |
| Jul 7, 2026 | Rodman & Renshaw | initiate | — → Buy | — | 40% |
| Apr 10, 2026 | Ascendiant Capital | maintain | Buy → Buy | — | 38% |
| Mar 26, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Dec 8, 2025 | Ascendiant Capital | maintain | Buy → Buy | $8 | 38% |
| Sep 22, 2025 | Ascendiant Capital | maintain | Buy → Buy | $7.75 | 38% |
| Jun 6, 2025 | Ascendiant Capital | maintain | Buy → Buy | $7.5 | 38% |
| Jun 5, 2025 | Craig-Hallum | initiate | — → Buy | $4 | 54% |
| Apr 21, 2025 | Ascendiant Capital | maintain | Buy → Buy | $7.25 | 38% |
| Mar 26, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $7 | 44% |
| Mar 12, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $7 | 44% |
| Jan 30, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $7 | 44% |
| Dec 13, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $7 | 44% |
| Dec 12, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $0 | 44% |
| Dec 9, 2024 | Ascendiant Capital | maintain | Buy → Buy | $7 | 38% |
| Nov 13, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $7 | 44% |
| Nov 5, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $6 | 44% |
| Oct 31, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $6 | 44% |
| Sep 11, 2024 | Ascendiant Capital | maintain | Buy → Buy | $6.5 | 38% |
| Aug 12, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $6 | 44% |
| Jun 28, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $6 | 44% |
| Jun 20, 2024 | Cantor Fitzgerald | reiterate | — → Overweight | $0 | 50% |
| Jun 6, 2024 | Ascendiant Capital | maintain | Buy → Buy | $6.25 | 38% |
| May 14, 2024 | Cantor Fitzgerald | reiterate | — → Overweight | $0 | 50% |
| May 13, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $6 | 44% |
| Apr 16, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $4 | 44% |
| Apr 2, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $4 | 44% |
| Feb 12, 2024 | HC Wainwright & Co. | initiate | — → Buy | $4 | 44% |
| Sep 8, 2023 | Cantor Fitzgerald | initiate | — → Overweight | $5 | 50% |
| Sep 17, 2020 | Ascendiant Capital | initiate | — → Buy | $7 | 38% |
| Dec 18, 2019 | Maxim Group | upgrade | Hold → Buy | $0 | 42% |
| Jan 26, 2018 | Maxim Group | initiate | — → Buy | $2 | 42% |
| Oct 7, 2013 | Sidoti & Co. | downgrade | Buy → Neutral | $0 | 38% |
| Apr 15, 2013 | Sidoti & Co. | initiate | — → Buy | $0 | 38% |
| Mar 20, 2013 | Dawson James | downgrade | Market Outperform → Buy | $16 | — |
Price Target Trend
Mar 30, 2026 Latest: $19 Oct 24, 2026
EPS Estimates
0q $-0.78
Lo: $-0.78 Hi: $-0.78
1 analysts ▲1
+1q $-0.78
Lo: $-0.78 Hi: $-0.78
1 analysts ▲1
+1y $-3.30
Lo: $-3.30 Hi: $-3.30
1 analysts ▲1
0y $-3.56
Lo: $-3.56 Hi: $-3.56
1 analysts ▲1
Cross-Platform Signals
No cross-platform signals in the last 90 days